C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function

Transplantation Proceedings

Volumn 37, Issue 3, 2005, Pages 1583-1585

  Dominguez J ^a,b,c   Fuenzalida, D ^a,b   Norambuena, R ^b   Pais, E ^b   Cortes Monroy, G ^b   Llanos, R ^b  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b HOSPITAL DR SÓTERO DEL RÍO   (Chile)

^c Rheumatology Service   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHOLESTEROL; CREATININE; CYCLOSPORIN A; STEROID; TRIACYLGLYCEROL; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DRUG MONITORING; FEMALE; HUMAN; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECIPIENT; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; ARTICLE; BLOOD; CHILE; CLINICAL TRIAL; COST; ECONOMICS; HEMATOCRIT; IMMUNOLOGY; KIDNEY FUNCTION TEST; KIDNEY TRANSPLANTATION; LIPID METABOLISM; METABOLIC CLEARANCE RATE; METHODOLOGY; PHYSIOLOGY; TIME;

ADULT; BLOOD UREA NITROGEN; CHILE; COSTS AND COST ANALYSIS; CREATININE; CYCLOSPORINE; DRUG MONITORING; FEMALE; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; LIPID METABOLISM; MALE; METABOLIC CLEARANCE RATE; TIME FACTORS;

EID: 19044391371     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.09.016     Document Type: Conference Paper

References (10)

1. B.D. Kahan, J. Dunn, C. Fitts Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals Transplantation 59 1995 505
2. A. Lindholm, B.D. Kahan Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation Clin Pharmacol Ther 54 1993 205
3. P. Belitsky, G.A. Levy, A. Johnston Neoral absorption profiling: an evolution in effectiveness Transplant Proc 32 Suppl 3A 2000 45S
4. K. Mahalati, P. Belitsky, I. Sketris Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation Transplantation 68 1999 55
5. K. Mahalati, J. Lawen, B. Kiberd Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period? J Urol 163 2000 37
6. J. Dominguez, A. Tomic, R. Norambuena Three-hour postdose cyclosporine level monitoring: less rejection and more nephrotoxicity? Transplant Proc 33 2001 3120
7. E. Thervet, P. Pfeffer, M.P. Scolari Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion Transplantation 76 2003 903
8. Kahan B: Management of the maintenance renal transplant recipient using Neoral C2 monitoring. A Transplant Odyssey. Abst PII.3. 48, 2001
9. P. Belitsky, T. Sitland, B. Kiberd Beneficial effects of adopting C2 monitoring in CyA me treated maintenace kidney transplant recipients monitored by C0 Transplantation 74 2002 58
10. G. Feutren, M.J. Mihatsch Risk factors for cyclosporine induced nephropathy in patients with autoimmune diseases. International kidney biopsy registry of cyclosporine in autoimmune diseases N Engl J Med 326 1992 1654